GlassScriptPhysician profile
Ryan J Beadle
NPI 1073525655
$5,114.49
in general payments reported to CMS, 2019-2025
29 companies · $937 in 2025
The $937 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $975 · 2023: $1,166 · 2024: $1,527 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.64 |
| Education | $246.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,007.55 | 2021-2025 | |
| Janssen Biotech, INC. | $670.22 | 2021-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $538.09 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $454.73 | 2021-2025 | |
| Amgen INC. | $361.36 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $262.46 | 2021-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $235.09 | 2021-2025 | Blu-U |
| Lilly USA, LLC | $223.02 | 2021-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $207.58 | 2021-2025 | |
| Leo Pharma INC. | $189.28 | 2022-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $134.50 | 2021 | |
| Incyte Corporation | $115.28 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $84.86 | 2022-2024 | Sotyktu |
| Genentech USA, INC. | $76.73 | 2021-2024 | Xolair |
| Pfizer INC. | $68.25 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $59.28 | 2022-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $57.14 | 2022 | |
| Dermavant Sciences, INC. | $52.03 | 2022-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $50.18 | 2023-2024 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.40 | 2023 | Spevigo |
| Merz North America, INC. | $37.40 | 2022 | |
| Strata Skin Sciences, INC. | $34.83 | 2023-2025 | Xtrac |
| Ucb, INC. | $30.00 | 2024 | Bimzelx |
| Kyowa Kirin, INC. | $24.85 | 2024 | Poteligeo |
| Organogenesis INC. | $23.35 | 2023 | Puraply |
| Biofrontera INC. | $22.01 | 2025 | Ameluz |
| Genentech, INC. | $18.80 | 2023 | Erivedge |
| Mimedx Group, INC. | $18.71 | 2025 | |
| Organon LLC | $7.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Beadle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.